BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients

Umberto Malapelle; Giulio Rossi; Pasquale Pisapia; Massimo Barberis; Fiamma Buttitta; Francesca Castiglione; Fabiana Letizia Cecere; Antonio Maria Grimaldi; Antonino Iaccarino; Antonio Marchetti; Daniela Massi; Daniela Medicina; Fabio Mele; Roberta Minari; Elisabetta Orlando; Fabio Pagni; Giuseppe Palmieri; Luisella Righi; Alessandro Russo; Stefania Tommasi; William Vermi; Giancarlo Troncone

doi:10.1016/j.critrevonc.2020.103118

BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients

Umberto Malapelle, Giulio Rossi, Pasquale Pisapia, Massimo Barberis, Fiamma Buttitta, Francesca Castiglione, Fabiana Letizia Cecere, Antonio Maria Grimaldi, Antonino Iaccarino, Antonio Marchetti, Daniela Massi, Daniela Medicina, Fabio Mele, Roberta Minari, Elisabetta Orlando, Fabio Pagni, Giuseppe Palmieri, Luisella Righi, Alessandro Russo, Stefania TommasiWilliam Vermi, Giancarlo Troncone

Istituto Nazionale Tumori Fondazione G. Pascale

Research output: Contribution to journal › Review article › peer-review

Abstract

In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian laboratories with high expertise in molecular predictive pathology testing is provided.

Original language	English
Article number	103118
Journal	Critical Reviews in Oncology/Hematology
Volume	156
DOIs	https://doi.org/10.1016/j.critrevonc.2020.103118
Publication status	Published - Dec 2020

Keywords

BRAF
Lung cancer
Melanoma
Precision medicine
Predictive molecular pathology

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.critrevonc.2020.103118

Fingerprint Dive into the research topics of 'BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients'. Together they form a unique fingerprint.

Cite this

Malapelle, U., Rossi, G., Pisapia, P., Barberis, M., Buttitta, F., Castiglione, F., Cecere, F. L., Grimaldi, A. M., Iaccarino, A., Marchetti, A., Massi, D., Medicina, D., Mele, F., Minari, R., Orlando, E., Pagni, F., Palmieri, G., Righi, L., Russo, A., ... Troncone, G. (2020). BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients. Critical Reviews in Oncology/Hematology, 156, [103118]. https://doi.org/10.1016/j.critrevonc.2020.103118

BRAF as a positive predictive biomarker : Focus on lung cancer and melanoma patients. / Malapelle, Umberto; Rossi, Giulio; Pisapia, Pasquale; Barberis, Massimo; Buttitta, Fiamma; Castiglione, Francesca; Cecere, Fabiana Letizia; Grimaldi, Antonio Maria; Iaccarino, Antonino; Marchetti, Antonio; Massi, Daniela; Medicina, Daniela; Mele, Fabio; Minari, Roberta; Orlando, Elisabetta; Pagni, Fabio; Palmieri, Giuseppe; Righi, Luisella; Russo, Alessandro; Tommasi, Stefania; Vermi, William; Troncone, Giancarlo.

In: Critical Reviews in Oncology/Hematology, Vol. 156, 103118, 12.2020.

Research output: Contribution to journal › Review article › peer-review

Malapelle, U, Rossi, G, Pisapia, P, Barberis, M, Buttitta, F, Castiglione, F, Cecere, FL, Grimaldi, AM, Iaccarino, A, Marchetti, A, Massi, D, Medicina, D, Mele, F, Minari, R, Orlando, E, Pagni, F, Palmieri, G, Righi, L, Russo, A, Tommasi, S, Vermi, W & Troncone, G 2020, 'BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients', Critical Reviews in Oncology/Hematology, vol. 156, 103118. https://doi.org/10.1016/j.critrevonc.2020.103118

Malapelle, Umberto ; Rossi, Giulio ; Pisapia, Pasquale ; Barberis, Massimo ; Buttitta, Fiamma ; Castiglione, Francesca ; Cecere, Fabiana Letizia ; Grimaldi, Antonio Maria ; Iaccarino, Antonino ; Marchetti, Antonio ; Massi, Daniela ; Medicina, Daniela ; Mele, Fabio ; Minari, Roberta ; Orlando, Elisabetta ; Pagni, Fabio ; Palmieri, Giuseppe ; Righi, Luisella ; Russo, Alessandro ; Tommasi, Stefania ; Vermi, William ; Troncone, Giancarlo. / BRAF as a positive predictive biomarker : Focus on lung cancer and melanoma patients. In: Critical Reviews in Oncology/Hematology. 2020 ; Vol. 156.

@article{cd40a8e0c965452d9b74e5e427a83fe1,

title = "BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients",

abstract = "In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian laboratories with high expertise in molecular predictive pathology testing is provided.",

keywords = "BRAF, Lung cancer, Melanoma, Precision medicine, Predictive molecular pathology",

author = "Umberto Malapelle and Giulio Rossi and Pasquale Pisapia and Massimo Barberis and Fiamma Buttitta and Francesca Castiglione and Cecere, {Fabiana Letizia} and Grimaldi, {Antonio Maria} and Antonino Iaccarino and Antonio Marchetti and Daniela Massi and Daniela Medicina and Fabio Mele and Roberta Minari and Elisabetta Orlando and Fabio Pagni and Giuseppe Palmieri and Luisella Righi and Alessandro Russo and Stefania Tommasi and William Vermi and Giancarlo Troncone",

year = "2020",

month = dec,

doi = "10.1016/j.critrevonc.2020.103118",

language = "English",

volume = "156",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - BRAF as a positive predictive biomarker

T2 - Focus on lung cancer and melanoma patients

AU - Malapelle, Umberto

AU - Rossi, Giulio

AU - Pisapia, Pasquale

AU - Barberis, Massimo

AU - Buttitta, Fiamma

AU - Castiglione, Francesca

AU - Cecere, Fabiana Letizia

AU - Grimaldi, Antonio Maria

AU - Iaccarino, Antonino

AU - Marchetti, Antonio

AU - Massi, Daniela

AU - Medicina, Daniela

AU - Mele, Fabio

AU - Minari, Roberta

AU - Orlando, Elisabetta

AU - Pagni, Fabio

AU - Palmieri, Giuseppe

AU - Righi, Luisella

AU - Russo, Alessandro

AU - Tommasi, Stefania

AU - Vermi, William

AU - Troncone, Giancarlo

PY - 2020/12

Y1 - 2020/12

N2 - In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian laboratories with high expertise in molecular predictive pathology testing is provided.

AB - In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian laboratories with high expertise in molecular predictive pathology testing is provided.

KW - BRAF

KW - Lung cancer

KW - Melanoma

KW - Precision medicine

KW - Predictive molecular pathology

UR - http://www.scopus.com/inward/record.url?scp=85092188397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85092188397&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2020.103118

DO - 10.1016/j.critrevonc.2020.103118

M3 - Review article

AN - SCOPUS:85092188397

VL - 156

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

M1 - 103118

ER -